Physician profile
Richard Link
NPI 1730114547
$1,219.62
in general payments reported to CMS, 2019-2025
17 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $170 · 2023: $187 · 2024: $389 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $274.86 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $189.25 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $133.64 | 2021-2022 | |
| Gilead Sciences, INC. | $88.23 | 2024-2025 | Epclusa |
| Pfizer INC. | $70.61 | 2023-2024 | |
| Exact Sciences Corporation | $68.26 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $65.59 | 2024 | Otezla, Repatha |
| Intra-Sana Laboratories | $56.09 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Novo Nordisk INC | $47.75 | 2024 | Ozempic, Rybelsus |
| Eisai INC. | $41.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.30 | 2022-2024 | |
| Glaxosmithkline, LLC. | $30.29 | 2024 | Trelegy Ellipta |
| Viiv Healthcare Company | $28.31 | 2025 | Cabenuva |
| Agios Pharmaceuticals, INC. | $27.03 | 2025 | Pyrukynd |
| Idorsia Pharmaceuticals US INC | $23.72 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $22.60 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.